Mutated fragment of vzv glycoprotein e
OwnerHaifeng SONG, Kai JI +1inventors
InventorsHaifeng SONG, Kai JI, Xishan LU
Life of this patent
Estimating the term…
Abstract
Provided herein are fragments of the gE protein of varicella-zoster virus and therapeutic nucleic acid molecules for managing, preventing and/or treating a disease or disorder caused by varicella-zoster virus or by infection therewith. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
Claims92
A protein comprising a mutant of a mature glycoprotein E (gE) of varicella-zoster virus (VZV), wherein the mutant comprises:
- (a) (i) a truncation of 37 amino acid residues from the C-terminus of the mature gE, and (ii) amino acid residue substitutions Y569A and Y582G, wherein amino acid residue positions 569 and 582 are the amino acid residue position numbers of full length VSV gE;
- (b) amino acid residue substitutions Y569A and Y582G, wherein amino acid residue positions 569 and 582 are the amino acid residue position numbers of full length VSV gE;
- (c) amino acid residue substitutions Y569A, Y582G, S593A, S595A, T596A, and T598A, wherein amino acid residue positions 569, 582, 593, 595, 596, and 598 are the amino acid residue position numbers of full length VSV gE;
- (d) amino acid residue substitutions Y582G, S593A, S595A, T596A, and T598A, wherein amino acid residue positions 582, 593, 595, 596, and 598 are the amino acid residue position numbers of full length VSV gE;
- or
- (e) (i) a truncation of 50 amino acid residues from the C-terminus of the mature gE protein, and (ii) amino acid residue substitution Y569A, wherein amino acid residue position 569 is the amino acid residue position number of full length VSV gE.
A fragment of a mature glycoprotein E (gE) of varicella-zoster virus (VZV), wherein the fragment comprises a truncation of at least one and at most 50, 49, 48, 47, 46, 45, 44, 43, or 42 amino acid residues from the C-terminal of the mature gE, optionally the truncation is a truncation of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 amino acid residues from the C-terminal of the mature gE, or optionally the truncation is a truncation of 11, 12, 13, 14, 15, 16, 17, 18, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 amino acid residues from the C-terminal of the mature gE, or optionally the truncation is a truncation of 14 or 37 amino acid residues from the C-terminal of the mature gE.
A fusion protein comprising a fragment of a mature glycoprotein (gE) of varicella-zoster virus (VZV) and a human IgE signal peptide, wherein the fragment comprises a truncation of 37 amino acid residues from the C-terminal of the mature gE, and the N-terminal of the fragment is fused to the C-terminal of the human IgE signal peptide.
A non-naturally occurring nucleic acid comprising the nucleotide sequence of SEQ ID NO:
- 63, 7, 51, 60, 62, 62, 64, 9, 11, 13, 52, 53, 54, 58, 49, 50, 4, or 5.
The non-naturally occurring nucleic acid of any one 50 to 59, wherein the nucleic acid is mRNA, and wherein thymines are substituted for uracils or a functional analog thereof in the nucleic acid.
Dependencies are inferred from the claim text.